Mesa Laboratories, Inc.

Equities

MLAB

US59064R1095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
89.94 ^USD	-1.33%		-1.47%	-14.15%

05/06	Earnings Flash (MLAB) MESA LABORATORIES Posts Q4 Revenue $58.9M, vs. Street Est of $55.3M	MT
05/06	Earnings Flash (MLAB) MESA LABORATORIES Posts Q4 EPS $2.77, vs. Street Est of $1.75	MT

Mesa Laboratories, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024

June 05, 2024 at 03:30 pm IST

Mesa Laboratories, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was USD 216.19 million compared to USD 219.08 million a year ago. Net loss was USD 254.25 million compared to net income of USD 0.93 million a year ago.

Basic loss per share from continuing operations was USD 47.2 compared to basic earnings per share from continuing operations of USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 47.2 compared to diluted earnings per share from continuing operations of USD 0.17 a year ago.

Latest news about Mesa Laboratories, Inc.

Earnings Flash (MLAB) MESA LABORATORIES Posts Q4 Revenue $58.9M, vs. Street Est of $55.3M	05/06	MT
Earnings Flash (MLAB) MESA LABORATORIES Posts Q4 EPS $2.77, vs. Street Est of $1.75	05/06	MT
Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024	05/06	CI
Mesa Laboratories, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	05/06	CI
Mesa Laboratories, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05/06	CI
Mesa Laboratories, Inc. Delays Earnings Announcement for the Fourth Quarter and Full Fiscal Year 2024 Results	22/05	CI
Mesa Laboratories, Inc. Amends and Restates Its Senior Secured Credit Agreement with Syndicate of Banks Led by JPMorgan Chase Bank, N.A	08/04	CI
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024	05/04	CI
Mesa Laboratories, Inc. announced that it expects to receive $71.25 million in funding	05/04	CI
Mesa Laboratories, Inc. Provides Impairment Guidance for the Fourth Quarter of 2024	02/04	CI
Earnings Flash (MLAB) MESA LABORATORIES Posts Q3 Revenue $53.5M	05/02	MT
Earnings Flash (MLAB) MESA LABORATORIES Reports Q3 EPS $2.02	05/02	MT
Mesa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	05/02	CI
Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors	08/01	CI
Mesa Laboratories Maintains Quarterly Dividend at $0.16 a Share, Payable March 15 to Shareholders of Record as of Feb. 29	05/01	MT
Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024	05/01	CI
Evercore ISI Upgrades Mesa Laboratories to Outperform From In-Line, Raises Price Target to $125 From $100	04/01	MT
Mesa Laboratories Completes Acquisition of GKE's Chinese Sales Entity	03/01	MT
Mesa Laboratories, Inc. acquired Beijing GKE Science & Technology Co. LTD for ?5 million	31/12	CI
Earnings Flash (MLAB) MESA LABORATORIES Posts Q2 Revenue $53.2M	06/11	MT
Earnings Flash (MLAB) MESA LABORATORIES Posts Q2 EPS $1.91	06/11	MT
Tranche Update on Mesa Laboratories, Inc.'s Equity Buyback Plan announced on November 10, 2005.	06/11	CI
Mesa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	06/11	CI
Mesa Laboratories Completes Acquisition of GKE's Sterilization Indicators Business, Testing Lab SAL	16/23/16	MT
Mesa Laboratories, Inc. entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for ?5 million.	16/23/16	CI

Chart Mesa Laboratories, Inc.

Duration

Period

More charts

Company Profile

Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters.

Sector

Medical Equipment, Supplies & Distribution

Calendar

01/08/2024 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Mesa Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

89.94 USD

Average target price

125 USD

Spread / Average Target

+38.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
MESA LABORATORIES, INC.	-14.15%	492M
ABBOTT LABORATORIES	-4.16%	183B
MEDTRONIC PLC	-2.39%	104B
BECTON, DICKINSON AND COMPANY	-4.08%	68.18B
CENCORA, INC.	+16.04%	47.14B
DEXCOM, INC.	-11.10%	43.97B
HOYA CORPORATION	+6.70%	40.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+17.63%	31.05B
WEST PHARMACEUTICAL SERVICES, INC.	-8.10%	24.11B
TERUMO CORPORATION	+12.48%	24.05B

Other Medical Equipment, Supplies & Distribution